Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Evaporator/Concentrator

November 8, 2012 12:59 pm | Product Releases | Comments

The Centrifan PE from KD Scientific is a small-volume evaporator for synthetic and medicinal chemists, as well as pharmaceutical, biotech, and university researchers.

TOPICS:

Meth Vaccine Shows Promise

November 8, 2012 12:42 pm | News | Comments

Scientists have performed successful tests of a methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication. If the vaccine proves effective in humans too, it could become the first specific treatment for meth addiction.

TOPICS:

Sun to Buy Dusa for $230M

November 8, 2012 11:34 am | News | Comments

Indian drugmaker Sun Pharmaceutical Industries Ltd. plans to buy dermatology company Dusa Pharmaceuticals Inc. in a cash deal worth about $230 million. Dusa's Levulan therapy uses light to treat skin disorders. Its products include the BLU-U treatment for moderate acne.

TOPICS:
Advertisement

Light-Based Remote Controls Proteins

November 8, 2012 3:00 am | by Stanford School of Medicine | News | Comments

Scientists have developed an intracellular remote control: a simple way to activate and track proteins, the busiest of cellular machines, using beams of light. The new method will let researchers shine light on a specific cell region to quickly activate a protein in that area.

TOPICS:

Agilent, Roche Sign Service Agreement

November 7, 2012 3:20 pm | News | Comments

Agilent Technologies Inc. and Roche announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services. Researchers use NimbleGen microarrays for many applications.

TOPICS:

Portola, BMS, and Pfizer Sign Collaboration

November 7, 2012 2:48 pm | News | Comments

Portola Pharmaceuticals Inc., Bristol-Myers Squibb Company, and Pfizer Inc. announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Eliquis. PRT4445 is a universal Factor Xa inhibitor antidote.

TOPICS:

Auxilium Ends Drug Marketing Deal

November 7, 2012 2:48 pm | News | Comments

Auxilium Pharmaceuticals Inc. has announced the end of a European partnership with Pfizer Inc. for its drug Xiaflex. The companies said the partnership will end by April 24. The news came as Auxilium reported its third-quarter results and trimmed its 2012 sales forecasts for the drug.

TOPICS:

ADX71441 Helps Control Binge Drinking

November 7, 2012 2:18 pm | News | Comments

Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced positive preclinical data for its GABA-B receptor positive allosteric modulator oral small molecule, ADX71441, in a validated rodent model of alcohol binge drinking.

TOPICS:
Advertisement

Doxepin Reduces Mouth Pain

November 7, 2012 2:06 pm | News | Comments

When used as a rinse, doxepin, a tricyclic antidepressant, reduces oral mucositis in patients who receive radiation therapy for head and neck cancer, according to research presented at the American Society for Radiation Oncology's 54th Annual Meeting.

TOPICS:

Biogen Idec Releases Phase 3 Results

November 7, 2012 2:00 pm | News | Comments

Biogen Idec and Swedish Orphan Biovitrum announced positive results from A-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia A. Hemophilia A is a rare inherited disorder that impairs blood coagulation.

TOPICS:

Reporter Assay

November 7, 2012 12:30 pm | Drug Discovery & Development | Product Releases | Comments

Enzo Life Sciences has introduced the Leading Light Wnt reporter assay. Alterations in Wnt expression, surface receptors, signaling partners, and the battery of Wnt-regulated genes are known to manifest in a variety of clinically relevant disease states.

TOPICS:

Microcarriers

November 7, 2012 12:26 pm | Drug Discovery & Development | Product Releases | Comments

Corning Incorporated announced a line of microcarriers for large-scale vaccine and cell therapy manufacturing. The microcarriers simplify the scale-up of attachment-dependent cells by providing a premeasured, sterile, ready-to-use product for direct transfer into bioreactors.

TOPICS:

Cage Incubator

November 7, 2012 12:21 pm | Drug Discovery & Development | Product Releases | Comments

Warner Instruments has introduced the Okolab Bold Line CO2 microscope cage incubator that provides a controlled environment all around the microscope.

TOPICS:

Humanized Mice Improve Drug Testing

November 7, 2012 12:11 pm | News | Comments

Scientists have used bioengineered mice with livers composed largely of human cells to characterize a drug about to enter early-stage clinical development for combating hepatitis C. Tests using the new mouse model accurately predicted significant aspects of the drug’s behavior in humans.

TOPICS:

Strangers' Stem Cells Repair Hearts

November 7, 2012 11:57 am | by Marilynn Marchione | News | Comments

Researchers are reporting a key advance in using stem cells to repair hearts damaged by heart attacks. In a study, stem cells donated by strangers proved as safe and effective as patients' own cells for helping restore heart tissue. The work proves the concept that anyone's cells can be used to treat such cases.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading